Related Experiment Videos
Pharmacoeconomic evaluation of risk factors for cardiovascular disease: an epidemiological perspective
1Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London.
Insights
Cost-effectiveness analyses for managing high blood pressure and high cholesterol show favorable outcomes in older men with multiple risk factors. Cheaper treatments offering greater risk reduction are most cost-effective.
Area of Science:
- Cardiovascular Disease
- Health Economics
- Pharmacological Treatment
Background:
- High blood pressure and hypercholesterolemia are key predictors of cardiovascular disease.
- Pharmacological treatments for these conditions represent a significant healthcare expenditure.
- Rising costs are anticipated for cholesterol-lowering therapies due to new, safer drugs.
Purpose of the Study:
- To analyze the cost-effectiveness of treatments for hypertension and hypercholesterolemia.
- To identify patient subgroups and treatment characteristics associated with favorable cost-effectiveness ratios.
- To inform decision-making regarding the optimal use of these pharmacological interventions.
Main Methods:
- Cost-effectiveness analysis applied to hypertension and hypercholesterolemia treatments.
- Evaluation of patient demographics (age, sex) and risk factor levels.
- Assessment of treatment costs and risk reduction efficacy.
Main Results:
- Optimal cost-effectiveness was observed in late middle-aged men with the highest risk factor levels and multiple risk factors.
- Least expensive treatments achieving the greatest risk reduction demonstrated the best cost-effectiveness.
- Key assumptions, such as similar morbidity/mortality effects across treatments for a given risk reduction, may be invalid.
Conclusions:
- Cost-effectiveness varies significantly by patient characteristics and treatment profile.
- Further research is needed to validate treatment efficacy assumptions and investigate benefits in underrepresented groups (women, elderly).
- The full burden of disease, including conditions like heart failure and vascular dementia, requires further study in relation to these risk factors.
Abstract:
Over the past 30 years the identification of high blood pressure and hypercholesterolaemia as major predictors of cardiovascular disease has led to an increasing expenditure on healthcare costs in pharmacological treatment of these risk factors. Most of the cost has been due to antihypertensive treatment, but evidence from randomised trials of the benefits of cholesterol-lowering drugs, along with the introduction of therapies with fewer side effects, suggests that expenditure on cholesterol treatment will rise dramatically. Cost-effectiveness analyses can aid decision making in the use of these treatments. For both hypertension and hypercholesterolaemia, the most favourable cost-effectiveness ratios were found in late middle age, in men compared to women, at the highest level of the risk factor, and in subjects with multiple risk factors. The most cost-effective treatments appear to be those which were the cheapest and which also produced the largest reductions in the risk factor. However, certain findings were based on assumptions which may be invalid. The most important of these in hypertension, and to a lesser extent in hypercholesterolaemia, is that different treatments have similar effects on morbidity and mortality for a given level of risk reduction. Experimental evidence that might confirm or refute this is not available for most treatments of hypertension. Moreover there are no trials in women or in the elderly of cholesterol-lowering treatments. The burden of disease due to these risk factors has been underestimated, and further research is required to establish the benefits of treatment on prevention of conditions such as heart failure, peripheral vascular disease, and vascular dementia.